Extrait

The main objective of the present study is to find out whether pre-treatment with the compound mangafodipir lowers the frequency and/or severity of FOLFOX6-related haematological toxicity and neurosensory toxicity in patients operated for colorectal cancer in stage Duke C.

Critère d'inclusion

• The study subjects will be patients with operated colorectal cancer stage Duke C who are going through standard FOLFOX6 treatment (5-FU, calcium-levofoliate and oxaliplatin). The objective of the study is to investigate whether mangafodipir (Teslascan) can lower the incidence of FOLFOX6-related adverse events and increase quality of life

Liens

• ictrp
• euctr